Tags

Type your tag names separated by a space and hit enter

[A new hydroxyethyl starch for volume replacement: Elohes 6%].
Rev Esp Anestesiol Reanim. 1998 Nov; 45(9):389-96.RE

Abstract

Various consensus groups convened in recent years to discuss plasma volume expansion solutions have suggested limiting the use of human albumin because of its high cost and have favored synthetic crystalloids or colloids for most clinical settings. Dextrans are colloids that are not widely used in most Europeans countries. Gelatins, in spite of the fact that unlimited amounts can be used, produce only moderate volume expansion and can trigger allergic reactions. The availability in Spain of hydroxyethylstarches (HES), a new type of colloid, may significantly change volume replacement strategy. HES are modified natural polymers. Three types, with different initial molecular weights, are used in Europe: high molecular weight HES, whose use in increasingly rare; low molecular weight HES (Expafusin), whose effect is short-lived; and medium molecular weight HES (Elohes, Fresenius-Laboratories Mein), which have recently been registered in Spain. Studies have shown that Elohes 6% (6% HES 200/0.62) provides volume expansion comparable to that of human albumin in clinical settings (cardiac surgery, shock, burns, etc.). The side effects of HES are usually minor. The frequency of anaphylactoid reactions is low, similar to that associated with human albumin. The effects on coagulation depend on molecular weight and duration of HES administration. Only in studies of hemodilution lasting 10 days with 6% HES 200/0.62 has VIII/von Willebrand complex been shown to decrease. If the recommended daily dose of this HES is respected, however, coagulation disorders are minimal. The effect of HES on kidney function is at present a subject of controversy. Thus, thanks to its prolonged effect on volume and few side effects, medium molecular weight HES colloids are the ones most often recommended for use in anesthesia and postoperative intensive care.

Authors+Show Affiliations

Servicio Nadia du Bouchet de Anestesia y Reanimación, Hospital Broussais, París, Francia.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

spa

PubMed ID

9847657

Citation

Medel, J, and J F. Baron. "[A New Hydroxyethyl Starch for Volume Replacement: Elohes 6%]." Revista Espanola De Anestesiologia Y Reanimacion, vol. 45, no. 9, 1998, pp. 389-96.
Medel J, Baron JF. [A new hydroxyethyl starch for volume replacement: Elohes 6%]. Rev Esp Anestesiol Reanim. 1998;45(9):389-96.
Medel, J., & Baron, J. F. (1998). [A new hydroxyethyl starch for volume replacement: Elohes 6%]. Revista Espanola De Anestesiologia Y Reanimacion, 45(9), 389-96.
Medel J, Baron JF. [A New Hydroxyethyl Starch for Volume Replacement: Elohes 6%]. Rev Esp Anestesiol Reanim. 1998;45(9):389-96. PubMed PMID: 9847657.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A new hydroxyethyl starch for volume replacement: Elohes 6%]. AU - Medel,J, AU - Baron,J F, PY - 1998/12/16/pubmed PY - 1998/12/16/medline PY - 1998/12/16/entrez SP - 389 EP - 96 JF - Revista espanola de anestesiologia y reanimacion JO - Rev Esp Anestesiol Reanim VL - 45 IS - 9 N2 - Various consensus groups convened in recent years to discuss plasma volume expansion solutions have suggested limiting the use of human albumin because of its high cost and have favored synthetic crystalloids or colloids for most clinical settings. Dextrans are colloids that are not widely used in most Europeans countries. Gelatins, in spite of the fact that unlimited amounts can be used, produce only moderate volume expansion and can trigger allergic reactions. The availability in Spain of hydroxyethylstarches (HES), a new type of colloid, may significantly change volume replacement strategy. HES are modified natural polymers. Three types, with different initial molecular weights, are used in Europe: high molecular weight HES, whose use in increasingly rare; low molecular weight HES (Expafusin), whose effect is short-lived; and medium molecular weight HES (Elohes, Fresenius-Laboratories Mein), which have recently been registered in Spain. Studies have shown that Elohes 6% (6% HES 200/0.62) provides volume expansion comparable to that of human albumin in clinical settings (cardiac surgery, shock, burns, etc.). The side effects of HES are usually minor. The frequency of anaphylactoid reactions is low, similar to that associated with human albumin. The effects on coagulation depend on molecular weight and duration of HES administration. Only in studies of hemodilution lasting 10 days with 6% HES 200/0.62 has VIII/von Willebrand complex been shown to decrease. If the recommended daily dose of this HES is respected, however, coagulation disorders are minimal. The effect of HES on kidney function is at present a subject of controversy. Thus, thanks to its prolonged effect on volume and few side effects, medium molecular weight HES colloids are the ones most often recommended for use in anesthesia and postoperative intensive care. SN - 0034-9356 UR - https://www.unboundmedicine.com/medline/citation/9847657/[A_new_hydroxyethyl_starch_for_volume_replacement:_Elohes_6]_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.